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Abstract
Background: Controversies surround a diagnosis of gestational diabetes mellitus (GDM). The objective of this study
was to evaluate the oral glucose tolerance test (OGTT) for the prediction of adverse gestational and perinatal
outcomes in pregnant women with a positive screening test for diabetes mellitus and a negative diagnosis, i.e. a
normal 3-hour OGTT.
Methods: This validation study evaluated 409 pregnant women who tested positive for diabetes mellitus at
screening. Perinatal and maternal outcomes were considered. Sensitivity and specificity were calculated for each of
the values of the OGTT as a diagnostic test, with the gold standard being perinatal outcome.
Results: The most frequent risk factors were obesity, arterial hypertension and advanced maternal age. The most
common neonatal outcomes were large-for-gestational-age infants, Cesarean delivery and preterm birth. A fasting
blood glucose level of 87 mg/dL was the most powerful predictor of adverse perinatal outcome.
Conclusions: At the cut-off level adopted by the American Diabetes Association, gestational OGTT was able to
successfully identify in which pregnant women outcome would be unfavorable.
Keywords: Gestational diabetes mellitus, Risk factors for gestational diabetes mellitus, Perinatal, Outcomes in gesta-
tional diabetes mellitus, Prenatal care
Background
Many controversies surround the diagnosis of gesta-
tional diabetes mellitus (GDM). In 1998, the American
Diabetes Association (ADA) recommended the adoption
of an oral glucose tolerance test (OGTT) using 100 or
75 g of dextrosol with well-defined cut-off limits for glu-
cose levels at fasting and following a glucose overload:
fasting < 95 mg/dL; 1 h < 180 mg/dL; 2 h < 155 mg/dL;
and 3 h < 140 mg/dL [1]. GDM is diagnosed when two
or more values are found to be above the established
cut-off limits. These recommendations were based on
studies conducted by O’Sullivan and Mahan, published
in 1964 [2] and adapted by Carpenter and Coustan in
1982 [3]. They have been maintained for the past 10
years [4].
The International Association of Diabetes and Preg-
nancy Study Groups (IADPSG) recommended the adop-
tion of certain markers for screening. If one of these
markers is present, an oral glucose tolerance test is then
performed. According to the guidelines proposed by
IADPSG, only one value above the cut-off limit in the 3-
hour OGTT is sufficient to justify a diagnosis of GDM. If
applied, this criterion will lead to a diagnosis of GDM in
18-20% of the entire obstetric population [5].
In parallel, a diabetes study group in Brazil developed a
consensus statement on the diagnosis and treatment of
diabetes in pregnancy. This consensus established the 2-
hour OGTT with 75 g of dextrosol as the standard diag-
nostic test, with a diagnosis of GDM being established
when at least two values are above the cut-off limits,
which coincide with those of the ADA proposal [4-6].
The thresholds adopted by the ADA for the 3-hour
OGTT are useful for diagnostic purposes in populations
similar to that of Brazil in which the prevalence of
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tested populations such as those of certain European
countries and the United States. The results established
in those populations formed the basis for defining the
current cut-off limits [4].
Screening, however, is still carried out based on the
presence of risk factors and by measuring fasting blood
glucose levels. If a woman has any of the risk factors or
if her fasting glucose level is ≥ 85 mg/dL, she is consid-
ered to have tested positive for GDM at screening [6].
The present study was performed to evaluate the pre-
valence of maternal and neonatal complications in
women who screened positive for GDM but who had a
normal 3-hour OGTT. An additional objective was to
assess the accuracy of the OGTT for the prediction of
adverse perinatal outcomes in this same population.
Methods
A study was conducted to validate a diagnostic test (3-
hour OGTT) in pregnant women who had screened
positive for GDM but who had a normal 3-hour, 100-
gram OGTT. The study was carried out at the Prof Dr
José A. Pinotti Women’s Hospital, a teaching hospital at
the State University of Campinas (UNICAMP), between
January 2000 and December 2009.
Sample size was calculated at 400 tests from 400 preg-
nant women. Overall, 409 tests from 409 patients were
evaluated. The inclusion criteria consisted of a positive
screening test for diabetes mellitus and an OGTT with
either only one value above the cut-off level or with all
values within the normal range (e.g. fasting glucose 95
mg/dL, 1-hour 180 mg/dL, 2-hour 155 mg/dL, 3-hour
140 mg/dL). To be considered positive at screening,
there had to be at least one risk factor (age ≥ 35 years,
previous GDM, family history of DM, previous macroso-
mic newborn infant, BMI ≥ 25 and chronic hyperten-
sion) or fasting blood glucose had to be ≥ 90 mg/dL.
Overall, 2,565 OGTT were performed during the study
period; however, 217 of the women vomited during the
test and it had to be stopped. In these cases, no further
gestational OGTT was performed. Of the remaining
2,348 tests, 1,123 women received a diagnosis of gesta-
tional diabetes mellitus. With respect to the other 1,225
OGTT performed, 803 referred to women who had
undergone prenatal care or had delivered their infant at
another clinic. Of the remaining 422 tests, criteria for
diagnosis were present in 10 cases, while 412 were con-
sidered normal. Of these, three were later excluded from
the data analysis because of fetal death. Therefore, 409
curves were included in the study (Figure 1).
The maternal variables evaluated were: age, body mass
index (BMI), weight, height, number of pregnancies,
parity, previous Cesarean delivery and gestational age at
time of delivery. The perinatal outcomes analyzed were:
macrosomia (birthweight > 4,000 grams), large-for-
gestational-age infants (LGA - birthweight above the
90
th percentile for GA at delivery), hydramnios (amnio-
tic fluid index above the 90
th percentile for GA), neona-
tal hypoglycemia (newborns with capillary blood glucose
< 40 mg/dL), neonatal hyperbilirubinemia (venous bilir-
ubin levels > 16 mg/dL), 5-minute Apgar score < 7, neo-
natal respiratory distress syndrome and C-section.
First, a descriptive analysis was performed and preva-
lence rates of maternal and perinatal variables were cal-
culated, together with their 95% confidence intervals
(95% CI). Receiver operating characteristic curves (ROC)
were constructed for the OGTT as a diagnostic test,
with the gold standard being the perinatal variables. The
area under the ROC curve was considered statistically
significant when it differed by 50%. The highest sensitiv-
ity and specificity values were considered the optimal
cut-off limits for the prediction of adverse perinatal
outcomes.
Data were stored and analyzed using the Excel soft-
ware program, version 6.0 b (Microsoft Corporation),
while the consistency of data was verified by performing
visual and statistical analyses in duplicate. The Internal
Review Board of this Medical School approved the study
under approval letter # 1131/2008.
Results
The median age of the women in this study was 29
years (range 15 to 45 years). Mean maternal weight was
74 kg (range 46.5 to 143.3 kg), while mean BMI was 29.
Median gestational age at birth was 38-39 weeks. Over-
all, 306 pregnant women (74.8%) had had two or more
previous pregnancies, while 98.7% had had at least one
previous delivery and 64% had had a previous C-section.
The most common risk factor was overweight, defined
as BMI ≥ 25 kg/m
2, with 60% of the women falling into
this category. Another important risk factor was chronic
hypertension (23%), followed by maternal age (20%) and
a family history of diabetes (20%). Thirty-seven percent
of the women had only one risk factor, while around
one-third had two or more risk factors. Fasting blood
glucose level was abnormal in about 10-12% of the
women; however, this constituted the only risk factor in
less than 2% of patients. Seventy-nine patients had no
risk factor and their fasting glucose levels were normal,
with only signs suggestive of overt diabetes such as fetal
macrosomia, excessive weight gain or hydramnios being
present (Table 1).
There was a high prevalence of LGA infants (19.3%
overall), an outcome that occurred in one-third of the
w o m e nw i t ha na b n o r m a lf a s t i n gg l u c o s el e v e la n di n
about one-fifth of those with only one risk factor. LGA
infants were also born to around a quarter of women
with two or more risk factors. No correlation was found
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absence of risk factors or serum glucose screening
values (Table 2).
A ROC curve was constructed for fasting blood glu-
cose levels. As shown in Table 3, sensitivity and specifi-
city for the fasting blood glucose curve were highest at
the value of 87 mg/dL for the prediction of LGA, which
was the most prevalent neonatal variable. However, the
area under the curve does not justify changing the cur-
rent cut-off points in the OGTT to this value (Figure 2).
With respect to the remaining OGTT values (60’, 120’,
180’), none of the values of the area under the ROC
curve differed by more than 50%; therefore, it was con-
cluded that there was no correlation with the perinatal
outcomes evaluated.
Table 1 Prevalence of risk factors and fasting glucose ≥
90 mg/dL (n = 409)
Risk factor N %
Fasting Glucose ≥ 90 mg% 47 11,5
Age ≥ 35 years 81 19,8
Previous GDM 13 3,2
Family history of DM 81 19,8
Previous macrosomia newborn 30 7,3
Body mass index (BMI) ≥ 25 244 59,8
Chronic hypertension 94 23,0
Suggestive clinical signs 79 19,3
GDM gestational diabetes mellitus
DM diabetes mellitus
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Figure 1 Flowchart illustrating the admission of pregnant women to the study.
Table 2 Distribution of perinatal outcomes according to risk factors (RF) and fasting glucose (FG)
Outcomes
Risk Factor Macrosoa
n/%
LGA
n/%
Hydramnio
n/%
Hypoglycemia
n/%
RDS
n/%
Hyperbilirubinemia
n/%
Fasting Glucose
2 or more (132) 16/12.1 34/25.7 11/8.3 2/1.5 3/2.2 3/2.2
Only one (151) 13/8.6 32/21.2 9/5.9 6/3.9 7/4.6 5/3.3
Glucose and others (41) 3/7.3 6/14.6 1/2.4 0/0 2/4.8 1/2.4
Only Glucose (6) 0/0 2/33.3 1/16.6 0/0 0/0 0/0
None (79) 3/3.7 5/6.3 4/5.0 4/5.0 3/3.7 0/0
Total (409) 35/8.5 79/19.3 26/6.3 12/2.9 15/3.6 9/2.2
RF risk factors
LGA large for gestational age
RDS respiratory distress syndrome
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In this study population, the most prevalent risk factors
were obesity or overweight, maternal age > 35 years,
chronic hypertension and excessive weight gain during
pregnancy. These data are in agreement with reports
published in the medical literature over the years [7,8].
Abnormal fasting blood glucose levels were not a rele-
vant indication for performing an OGTT. This finding
contradicts what has been established in the literature in
which this is highlighted as constituting a basic para-
meter [9]. However, when blood glucose is associated
with a risk factor, it gains importance as an indication
for performing an OGTT [10,11]. It should be empha-
sized that clinical signs during pregnancy such as mater-
nal weight gain, fetal weight and increased amniotic
fluid are strongly related to glucose intolerance and
should signal a need to request an OGTT. In the popu-
lation studied, 32.3% of the sample fulfilled these cri-
teria. This finding is supported in the literature by
studies such as those carried out by Ferrara and Agarwal
[12,13].
When the results of the OGTT were compared with
the outcome of pregnancy as the gold standard, it was
found that there are no cut-off limits other than those
already established that are capable of forecasting signif-
icant differences, except for fasting blood glucose levels
for which the best cut-off limit would be 87 mg/dl.
It must be noted that from a methodological point of
view, there were few useful values available with which
to construct the ROC curve, which may have hampered
analysis to a certain extent. To construct these ROC
curves, cumulative numbers were used that focused on
Table 3 Sensitivity and specificity of OGTT in predicting
large for gestational age newborns
Fasting glucose Sensitivity (95% CI) Specificity (95% CI)
≤ 84 mg/dl 69.6 (59.5-79.8) 29.1 (24.2-34.0)
85 mg/dl 74.7 (65.1-84.3) 26.1 (21.3-30.8)
86 mg/dl 81.0 (72.4-89.7) 21.2 (16.8-25.6)
87 mg/dl 86.1 (78.4-93.7) 18.5 (14.3-22.7)
88 mg/dl 88.6 (81.6-95.6) 14.2 (10.5-18.0)
89 mg/dl 89.9 (83.2-96.5) 11.8 (8.3-15.3)
90 mg/dl 89.9 (83.2-96.5) 9.1 (6.0-12.2)
91 mg/dl 89.9 (83.2-96.5) 7.6 (4.7-10.4)
92 mg/dl 91.1 (84.9-97.4) 7.0 (4.2-9.7)
93 mg/dl 92.4 (86.6-98.2) 5.2 (2.8-7.5)
94 mg/dl 92.4 (86.6-98.2) 4.2 (2.1-6.4)
≥ 95 mg/dl 100.0 0.0
95% CI 95% confidence interval
OGTT oral glucose tolerance test
 
Figure 2 “ROC” curve for oral glucose tolerance test values according to the most prevalent outcome (LGA).
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technique the cut- off limit is shifted to lower numbers.
Another limitation of the study was the fact that neo-
natal variables were used as the gold standards, and
these are likely to be affected by several other factors,
unlike the markers that have been used specifically for
GDM and dysglycemia such as cord blood C-peptide
and the percentage of body fat in the neonate [14].
These markers are highly specific for GDM and meta-
bolic disturbances, and are used to identify pregnant
women in whom metabolic changes are minimal [15].
However, in terms of perinatal care in developing coun-
tries where resources are sparse, this strategy of placing
the emphasis on clinical data appears extremely timely
and useful.
Naturally, in studies involving larger samples such as
the HAPO study, values other than those obtained in
the present study may be found. In our study, there was
a high prevalence of LGA infants born to women with a
normal OGTT (according to the ADA guidelines) and
risk factors such as advanced maternal age, obesity and
chronic hypertension, associated or not with abnormal
fasting blood glucose [4,11,16].
Conclusion
In conclusion, 3-hour OGTT, as recommended by the
ADA [4] and adopted for use in Brazil, is adequate for
establishing a diagnosis of GDM in this population and
there is no need to change the current established cut-
off limits.
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